Search: WFRF:(Porwit MacDonald A)
> (2003) >
A validated decisio...
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor : Significant effects on quality of life
-
- Hellstrom-Lindberg, E. (author)
- Karolinska Institutet,Hellström-Lindberg, E., Department of Medicine, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden, Department of Medicine, Karolinska Institute, Huddinge University Hospital, 141 86 Stockholm, Sweden
-
- Gulbrandsen, N. (author)
- Department of Haematology, Ullevål Hospital, Oslo, Norway
-
- Lindberg, G. (author)
- Karolinska Institutet,Department of Medicine, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
-
show more...
-
- Ahlgren, T. (author)
- Depts. Med./Haematol. the Hospitals, Malmö, Sweden
-
- Dahl, I.M.S. (author)
- Depts. Med./Haematol. the Hospitals, Tromsö, Norway
-
- Dybedal, I. (author)
- Depts. Med./Haematol. the Hospitals, Trondheim, Norway
-
- Grimfors, G. (author)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Blodsjukdomar
-
- Hesse-Sundin, E. (author)
- Karolinska Hospital, Eskilstuna, Sweden
-
- Hjorth, M. (author)
- Karolinska Hospital, Lidköping, Sweden
-
- Kanter-Lewensohn, L. (author)
- Karolinska Institutet,Department of Pathology, Karolinska Hospital, Stockholm, Sweden
-
- Linder, O. (author)
- Karolinska Hospital, Örebro, Sweden
-
- Luthman, M. (author)
- St. Göran Hospital, Stockholm, Sweden
-
- Lofvenberg, E. (author)
- Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi,Onko
-
- Oberg, G. (author)
- Öberg, G., St. Göran Hospital, Uppsala, Sweden
-
- Porwit-MacDonald, A. (author)
- Karolinska Institutet,Department of Pathology, Karolinska Hospital, Stockholm, Sweden
-
- Rådlund, Anders (author)
- Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Onkologi,Onkologiska kliniken US
-
- Samuelsson Johannesson, Jannica (author)
- Karolinska Institutet,Lund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine,Southern Hospital, Stockholm, Sweden
-
- Tangen, J.M. (author)
- Department of Haematology, Ullevål Hospital, Oslo, Norway
-
- Winquist, I. (author)
- Southern Hospital, Lund, Sweden
-
- Wisloff, F. (author)
- Department of Haematology, Ullevål Hospital, Oslo, Norway
-
show less...
-
Karolinska Institutet Hellström-Lindberg, E, Department of Medicine, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden, Department of Medicine, Karolinska Institute, Huddinge University Hospital, 141 86 Stockholm, Sweden (creator_code:org_t)
- 2003-03-18
- 2003
- English.
-
In: British Journal of Haematology. - : Wiley. - 0007-1048 .- 1365-2141. ; 120, s. 1037-
- Related links:
-
https://onlinelibrar...
-
show more...
-
http://dx.doi.org/10...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
http://kipublication...
-
https://urn.kb.se/re...
-
show less...
Abstract
Subject headings
Close
- We have published previously a prototype of a decision model for anaemic patients with myelodysplastic syndromes (MDS), in which transfusion need and serum erythropoietin (S-Epo) were used to define three groups with different probabilities of erythroid response to treatment with granulocyte colony-stimulating factor (G-CSF) + Epo. S-Epo = 500 U/l and a transfusion need of < 2 units/month predicted a high probability of response to treatment, S-Epo > 500 U/l and =2 units/month for a poor response, whereas the presence of only one negative prognostic marker predicted an intermediate response. A total of 53 patients from a prospective study were included in our evaluation sample. Patients with good or intermediate probability of response were treated with G-CSF + Epo. The overall response rate was 42% with 28.3% achieving a complete and 13.2% a partial response to treatment. The response rates were 61% and 14% in the good and intermediate predictive groups respectively. The model retained a significant predictive value in the evaluation sample (P < 0.001). Median duration of response was 23 months. Scores for global health and quality of life (QOL) were significantly lower in MDS patients than in a reference population, and fatigue and dyspnoea was significantly more prominent. Global QOL improved in patients responding to treatment (P = 0.01). The validated decision model defined a subgroup of patients with a response rate of 61% (95% confidence interval 48-74%) to treatment with G-CSF + Epo. The majority of these patients have shown complete and durable responses.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Keyword
- Anaemia
- Erythropoietin
- Granulocyte colony-stimulating factor
- Myelodysplasia
- MEDICINE
- MEDICIN
- granulocyte colony-stimulating factor
- anaemia
- erythropoietin
- myelodysplasia
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Hellstrom-Lindbe ...
-
Gulbrandsen, N.
-
Lindberg, G.
-
Ahlgren, T.
-
Dahl, I.M.S.
-
Dybedal, I.
-
show more...
-
Grimfors, G.
-
Hesse-Sundin, E.
-
Hjorth, M.
-
Kanter-Lewensohn ...
-
Linder, O.
-
Luthman, M.
-
Lofvenberg, E.
-
Oberg, G.
-
Porwit-MacDonald ...
-
Rådlund, Anders
-
Samuelsson Johan ...
-
Tangen, J.M.
-
Winquist, I.
-
Wisloff, F.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Hematology
- Articles in the publication
-
British Journal ...
- Br J Haematol
- By the university
-
Linköping University
-
Lund University
-
Karolinska Institutet
-
Uppsala University